EDAP to Report Third Quarter 2016 Financial Results on November 17, 2016
November 03 2016 - 7:30AM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today that it plans to release financial
results for the third quarter ended September 30, 2016 on Thursday,
November 17, 2016, during pre-market hours.
Company management will host a conference call on
Thursday, November 17, 2016 at 8:30 a.m. ET to discuss the results
and provide an update on business developments. To
participate in the call, please dial 1-888-348-6419 in the U.S., or
1-412-902-4235 internationally. The conference ID number is
10095751. A live webcast of the conference call will be available
on the investor relations page of the Company’s corporate website
at www.edap-tms.com.
After the live event, the webcast will remain
available on EDAP’s website through December 19, 2016. In
addition, a dial-in replay of the call will be available until
September 3, 2016. The telephone replay can be accessed by
calling 1-844-512-2921 in the U.S. or 1-412-317-6671
internationally. Please use event passcode 10095751.
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and for
treatment of localized prostate cancer in the rest of the world.
HIFU treatment is shown to be a minimally invasive and effective
option for prostatic tissue ablation with a low occurrence of side
effects. Ablatherm is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for
surgery or who prefer an alternative option, or for patients who
failed radiotherapy treatment. Ablatherm is approved for commercial
distribution in Europe and other countries including Mexico and
Canada, and has received 510(k) clearance by the U.S. FDA. The
Company also markets an innovative robot-assisted HIFU device, the
Focal One®, dedicated to focal therapy of prostate cancer. Focal
One® is CE marked but is not FDA approved. The Company also
develops its HIFU technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and distributes
medical equipment (the Sonolith® lithotripters' range) for the
treatment of urinary tract stones using extra-corporeal shockwave
lithotripsy (ESWL) in most countries including Canada and the U.S.
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also may include,
but are not limited to, those described in the Company's filings
with the Securities and Exchange Commission and in particular, in
the sections "Cautionary Statement on Forward-Looking Information"
and "Risk Factors" in the Company's Annual Report on Form 20-F.
Contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Lee Roth
The Ruth Group
646-536-7012
lroth@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jun 2024 to Jul 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Jul 2023 to Jul 2024